Sugi Predict

Sugi Predict / Compounds / SCHEMBL3375350

SCHEMBL3375350

SCHEMBL3375350

CCOC(=O)N1C=CCc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ GAA P10253 1/20 0.43
▸ ALDH1A1 P00352 7/20 0.43
▸ NOTUM Q6P988 1/20 0.43
▸ KMT2A Q03164 3/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ LMNA P02545 3/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ OPRM1 P35372 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ SLC22A1 O15245 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ OPRD1 P41143 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6110995 0.90 ALDH1A1 (0.41) BCHESMN1; SMN2GAAALDH1A1NOTUM
SCHEMBL3719676 0.88 BCHE (0.50) BCHESMN1; SMN2ALDH1A1KMT2AKDM4E
SCHEMBL6110404 0.86 P2RX4 (0.50) SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1
SCHEMBL27711169 0.84 P2RX4 (0.42) BCHESMN1; SMN2ALDH1A1NOTUMKMT2A
SCHEMBL5670700 0.81 BCHE (0.46) BCHENOTUMKMT2AMEN1POLB
SCHEMBL6110762 0.81 P2RX4 (0.46) BCHESMN1; SMN2GAAALDH1A1NOTUM
SCHEMBL6980620 0.78 POLB (0.54) BCHESMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL7834810 0.77 KDM4E (0.40) SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1
SCHEMBL10841005 0.77 NPC1 (0.39) SMN1; SMN2ALDH1A1NOTUMKMT2AMEN1
SCHEMBL1629578 0.77 NPC1 (0.39) SMN1; SMN2ALDH1A1NOTUMKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670446-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2006-06-21 — — EP claimed
WO-2006033004-A1 QUINOLINE COMPOUNDS AS CETP INHIBITORS PFIZER PRODUCTS INC. (US) 2006-03-30 — — WO claimed
WO-2005030185-A2 METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION JAPAN TOBACCO INC. (JP) 2005-04-07 — — WO claimed
EP-1305007-A2 PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS Pfizer Products Inc. (US) 2003-05-02 — — EP claimed
WO-2002011710-A2 PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2002-02-14 — — WO claimed
CN-119954828-A Parallel ring compound and preparation and application thereof 石药集团中奇制药技术（石家庄）有限公司 2025-05-09 — — CN disclosed
CN-116322699-B Parallel ring compound and preparation and application thereof 石药集团中奇制药技术（石家庄）有限公司 2025-02-11 — — CN disclosed
CN-116322699-A Parallel ring compound and preparation and application thereof 石药集团中奇制药技术（石家庄）有限公司 2023-06-23 — — CN disclosed
WO-2022063303-A1 A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF 石药集团中奇制药技术（石家庄）有限公司 2022-03-31 — — WO disclosed
US-20160355515-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER ARQULE, INC. 2016-12-08 — — US disclosed
EP-2396003-B1 A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib ARQULE INC (US) 2013-04-17 — — EP disclosed
EP-2289892-B1 Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer ARQULE INC (US) 2012-08-22 — — EP disclosed
WO-2003000226-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMER AND DRUG ASSEMBLIES PFIZER PRODUCTS INC. (US) 2003-01-03 — — WO disclosed
WO-2002088085-A2 METHODS AND INTERMEDIATES FOR PREPARING 4-AMINOQUINOLINE CETP INHIBITORS PFIZER PRODUCTS INC. (US) 2002-11-07 — — WO disclosed
WO-2002012442-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR NEUROGEN CORPORATION (US) 2002-02-14 — — WO disclosed
WO-2002011710-A2 PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2002-02-14 — — WO disclosed
EP-1114031-A1 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS Pfizer Products Inc. (US) 2001-07-11 — — EP disclosed
EP-1114032-A1 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS Pfizer Products Inc. (US) 2001-07-11 — — EP disclosed
WO-2000017165-A1 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS PFIZER PRODUCTS INC. (US) 2000-03-30 — — WO disclosed
WO-2000017164-A1 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS PFIZER PRODUCTS INC. (US) 2000-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160355515-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER MKI67, NUP205, TP53 BCHE 2752/4885SMN1; SMN2 2196/4885GAA 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.